TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10420072
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin, Fragmin(R), 10,000 IU s.c. once daily)
Study: 10420072
Drug: Coumarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin therapy
Study: 28339668
Drug: MCV4 booster
Normalized name: meningococcal MCV4, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV4 booster dose
Study: 22882249
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) 12 IU
Study: 22882249
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) 24 IU
Study: 22882249
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) (all doses)
Study: 22882249
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI) 12 IU
Study: 22882249
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI) 24 IU
Study: 14706125
Drug: Megace OS
Normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megace OS (400 mg daily for 63 days)
Study: 11593128
Drug: Midazolam, fentanyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, fentanyl, and alfentanil as supplemental agents
Study: 7950196
Drug: Persantin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persantin and Aspirin
Study: 25329142
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolone
Study: 25329142
Drug: Heated lidocaine/tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated lidocaine/tetracaine (Trilexis) patch
Study: 9883300
Drug: Tri-Nasal Nasal
Normalized name: Tri-Nasal Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-Nasal Nasal Spray 200 micrograms qd
Study: 9883300
Drug: Tri-Nasal Nasal
Normalized name: Tri-Nasal Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-Nasal Nasal Spray 400 micrograms qd
Study: 2213395
Drug: 400 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg IVIG daily for 4 days
Study: 2213395
Drug: 1 gm/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm/kg IVIG as a single dose
Study: 28385543
Drug: Rosuvastatin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (single doses)
Study: 28385543
Drug: Rosuvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin with intravenous rifampin (inhibited condition)
Study: 25281416
Drug: Laquinimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.5 mg/day
Study: 25281416
Drug: Laquinimod 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 1.0 mg/day
Study: 23448846
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy for hypertension
Study: 23448846
Drug: Demographic factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic factors (male gender, living in a regional area) and clinical factors (history of antihypertensive therapy, increased plasma creatinine, lower pretreatment pulse pressure, in-study use of multiple BP-lowering drugs)
Study: 15290658
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg (n = 5068)
Study: 15290658
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (n = 1243)
Study: 15290658
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (n = 3018)
Study: 15290658
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (n = 2616)
Study: 12536732
Drug: Intraoperative application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative application of mitomycin C (MMC) 0.4 mg/ml for 1 minute
Study: 9678108
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (all preparations)
Study: 9678108
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (desogestrel/ethinylestradiol 150/20)
Study: 3549413
Drug: Propranolol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (doses that reduced resting heart rate by 25%)
Study: 29155195
Drug: CDDU +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDU + ICI (10 µg alprostadil) repeated assessments (maximum of 3 rounds)
Study: 29155195
Drug: CDDU +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDU + ICI (10 µg alprostadil) before and after sexological counseling
Study: 16930101
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (3mg)
Study: 10680790
Drug: 3,4-diaminopyridine (DAP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-diaminopyridine (DAP), 20 mg three times daily for 6 days
Study: 9375332
Drug: Inhalation rewarming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation rewarming with saturated air at approximately 43 degrees C
Study: 7654578
Drug: Amorolfine spray
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine spray 0.5%
Study: 7654578
Drug: Amorolfine spray
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine spray 2%
Study: 7654578
Drug: Amorolfine spray
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine spray (both concentrations)
Study: 3300174
Drug: Declined pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Declined pump treatment
Study: 29784057
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) tapering first
Study: 29784057
Drug: Vasopressin (AVP)
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin (AVP) tapering first
Study: 27211885
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care with thymol
Study: 20602016
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam‐beta‐cyclodextrin
Study: 20602016
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg piroxicam‐beta‐cyclodextrin
Study: 1952847
Drug: Temafloxacin hydrochloride
Normalized name: temafloxacin hydrochloride
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin hydrochloride (400 mg once a day for 7 days)
Study: 1952847
Drug: Trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (160 mg) and sulfamethoxazole (800 mg) (TMP-SMZ) twice daily for 10 days
Study: 27344987
Drug: Existing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing therapy (self-formulated dexamethasone mouth rinse)
Study: 21272091
Drug: Silodosin at
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin at 4 mg twice a day
Study: 21272091
Drug: Tamsulosin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin at 0.2 mg once a day
Study: 21272091
Drug: Naftopidil at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil at 50 mg once a day
Study: 16772812
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg/d
Study: 29287276
Drug: Noninvasive measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive measures (e.g., the use of a 'soft room', observation in seclusion)
Study: 29287276
Drug: Invasive measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive measures (e.g., mechanical restraint, forced medication)
Study: 29287276
Drug: Forced medication
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced medication and mechanical restraint
Study: 29287276
Drug: Options for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Options for reducing coercion (e.g., music or exercises)
Study: 25448515
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of intramuscular 17OHP‐C weekly until 36 weeks
Study: 20559296
Drug: Naltrexone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 591)
Study: 20559296
Drug: Naltrexone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 482)
Study: 20559296
Drug: Naltrexone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 301)
Study: 20559296
Drug: Naltrexone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD
Study: 10392861
Drug: Poloxamer 188
Normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer 188 as ancillary therapy to thrombolysis
Study: 1846784
Drug: Sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 320 mg/24 hr
Study: 1846784
Drug: Sotalol 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 640 mg/24 hr
Study: 23681677
Drug: Parent-child interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-child interaction therapy (immediate treatment)
Study: 16821204
Drug: Alendronate (ALN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (ALN), 10 mg daily for 2 years
Study: 7734258
Drug: 51W89 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51W89 (0.1 mg kg‐1, 2 x ED95)
Study: 7734258
Drug: Atracurium (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.4 mg kg‐1)
Study: 2789932
Drug: Yohimbine (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (14 mg)
Study: 4154818
Drug: Fluoride topical
Normalized name: fluoride topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride topical application twice a year (Group 3)
Study: 4154818
Drug: Fluoride topical
Normalized name: fluoride topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride topical application once a year (Group 2)
Study: 29432772
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (L. acidophilus, L. plantarum, L. fermentum, L. gasseri with fructooligosaccharide for 6 weeks)
Study: 24417565
Drug: Self-administered checklist
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered checklist
Study: 23652044
Drug: 45 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/m2 gambogic acid intravenously from Days 1 to 5 of a 2-week cycle (Group A)
Study: 23652044
Drug: 45 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/m2 gambogic acid every other day for a total of five times during a 2-week cycle (Group B)
Study: 21322147
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day) and Fluoxetine (20 mg/day) for 6 months
Study: 21322147
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and Fluoxetine placebo
Study: 21322147
Drug: Naltrexone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone placebo and Fluoxetine
Study: 21322147
Drug: Naltrexone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone placebo and Fluoxetine placebo
Study: 16871932
Drug: Topical mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mitomycin-C (MMC) applied at a concentration of 0.5 mg/mL for 4 minutes post-frontal sinusotomy.
Study: 14696846
Drug: Beta-glucuronidase activity
Normalized name: Recombinant human beta-glucuronidase
DrugBank: Vestronidase alfa (DB12366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Beta-glucuronidase activity in CSF before treatment
Study: 15235963
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of 0.25% bupivacaine at a rate of 2‐5 ml.hr(‐1)
Study: 15235998
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.125% or 0.25% bupivacaine and 0.0025% or 0.005% morphine at a rate of 2‐4 ml.hr(‐1)
Study: 788570
Drug: Streptomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin plus isoniazid plus pyrazinamide twice a week
Study: 21252501
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of AM-101
Study: 17367658
Drug: Aliskiren (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (all doses)
Study: 9789646
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antibiotics
Study: 7811656
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg intranasal midazolam
Study: 30803175
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium sulfate solution in split doses (group A, n=178)
Study: 30803175
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose group (group B, n=190)
Study: 29327733
Drug: Functional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional therapy of mandibular advancement
Study: 25400085
Drug: Thrice-daily regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily regimen of oral hydrocortisone (OHC)
Study: 12558913
Drug: CIFN 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN 9 microg daily
Study: 12558913
Drug: CIFN 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN 9 microg daily plus ribavirin 1000 or 1200 mg daily
Study: 10736983
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg/die)
Study: 1601147
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) - leuprolide acetate (500 micrograms)
Study: 6397871
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral anticoagulation with shorter heparin treatment
Study: 6397871
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral anticoagulation with conventional heparin treatment
Study: 6397871
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral anticoagulation with shorter heparin treatment (second part of the study)
Study: 6397871
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral anticoagulation with conventional heparin treatment (second part of the study)
Study: 31144435
Drug: GLP1RA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP1RA plus basal insulin
Study: 28405346
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin
Study: 26990766
Drug: AQW051 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQW051 10 mg
Study: 26990766
Drug: AQW051 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQW051 50 mg
Study: 21253451
Drug: Fluticasone Propionate/Salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI)
Study: 17689205
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking cessation treatment during alcohol treatment
Study: 17689205
Drug: Delayed smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed smoking cessation treatment (6 months later)
Study: 15897722
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of d-amphetamine
Study: 12917721
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (intensive treatment)
Study: 12917721
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (less intensive treatment)
Study: 10150320
Drug: Single 5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5-mg dose of ramipril
Study: 10150320
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of 5 mg of ramipril daily for 6 months
Study: 2201190
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg per day for 2 days)
Study: 7003434
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Shunt removal with systemic antibiotics, external ventricular drainage or intermittent ventricular taps for decompression and antibiotic administration; intravenous and intraventricular antibiotics for a minimum of 7 days.
Study: 7003434
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Removal and immediate replacement of the shunt with intrashunt antibiotic therapy; intravenous antibiotics for a minimum of 3 weeks and twice daily intraventricular antibiotics for a minimum of 2 weeks.
Study: 7003434
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Antibiotics without removal or replacement of the shunt; intravenous antibiotics for a minimum of 3 weeks and twice daily intraventricular antibiotics for a minimum of 2 weeks.
Study: 30975954
Drug: 150‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150‐mg oral pregabalin and 400 mg IV ibuprofen
Study: 30975954
Drug: 75‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75‐mg oral pregabalin and 400‐mg IV ibuprofen
Study: 30975954
Drug: 400‐mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐mg IV ibuprofen
Study: 30975954
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo and IV placebo
Study: 30975954
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo and 400‐mg IV ibuprofen
Study: 28231660
Drug: Telbivudine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine treatment during second and third trimesters of pregnancy
Study: 28231660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no telbivudine treatment)
Study: 26297142
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² followed by cisplatin 75 mg/m² (Arm A)
Study: 26297142
Drug: Docetaxel +
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + cisplatin with esomeprazole (ESOM) 80 mg p.o. bid for 3 days (Arm B)
Study: 26297142
Drug: Docetaxel +
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + cisplatin with esomeprazole (ESOM) 100 mg p.o. bid for 3 days (Arm C)
Study: 26297142
Drug: PPI (Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (Proton Pump Inhibitors) vs no PPI
Study: 26297142
Drug: PPI combination
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI combination in triple negative breast cancer (TNBC)
Study: 26297142
Drug: PPI combination
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI combination effect on overall survival (OS)
Study: 23273588
Drug: 1,000 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mL/d fluid restriction
Study: 22040597
Drug: Sham intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham intervention (de-tuned ultrasound and de-tuned activator treatment)
Study: 19148431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of IV cephazolin in the anesthetic induction (Group C)
Study: 19148431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of tinidazole orally, 12 hours before the surgery (Group T)
Study: 19148431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of tinidazole orally 12 hours before the surgery and 2g of IV cephazolin in the anesthetic induction (Group C+T)
Study: 16572441
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with etanercept (25 mg subcutaneously twice weekly) and oral MTX (up to 20 mg weekly)
Study: 16572441
Drug: Methotrexate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (up to 20 mg weekly)
Study: 11138459
Drug: Epirubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (70 mg/m2) days 1 and 8 every 4 weeks
Study: 11138459
Drug: Epirubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (60 mg/m2) days 1 and 8 plus cisplatin (100 mg/m2) day 1 every 4 weeks
Study: 1567032
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 100 micrograms/10 mL
Study: 1567032
Drug: Normal saline-control
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline-control 10 mL
Study: 3926067
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream, applied topically five times a day for five days
Study: 30509268
Drug: Correct inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct inhalation technique
Study: 30509268
Drug: Incorrect inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect inhalation technique